Business
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting taking place virtually on May 12-15, 2020.\n The ASGCT abstracts are now available at https://www.asgct.org/. Details for the oral presentations are as follows: Title: Development of AAV-based RNAi Therapeutics for Huntington’s DiseaseSession: Scientific SymposiumDate/time: May 12, 2020, 9:18-9:45 a.m. ET Title: Engineering Viral Protein Ratios to Impact AAV PotencySession: AAV Vectors - Clinical Studies IIDate/time: May 13, 2020, 5:00-5:15 p.m. ET Title: Lac Repressor Inducible Control of AAV Capsid Protein Ratios and Decoupling VP1, VP2 from VP3 in the Sf9 insect cell/Baculovirus Expression Vector (BEV) PlatformSession: Vector and Cell Engineering, Production, or Manufacturing IVDate/time: May 14, 2020, 5:15-5:30 p.m. ET Details for the poster presentations are as follows: Title: Phenotypic Benefit of Intrastriatal Administration of the AAV Gene Therapy VY-HTT01 in the YAC128 Mouse Model of Huntington’s DiseaseSession: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/time: May 12, 2020, 5:30-6:30 p.m. ET Title: Intraparenchymal Spinal Cord Delivery of AAV VY-SOD102 Reduces Disease Burden in the G93A Mouse Model of ALS-SOD1Session: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/time: May 12, 2020, 5:30-6:30 p.m. ET Title: Robust Scale-Up and Production of Multiple Gene Therapy Vectors for Pre-Clinical Applications at 250 L Scale with the Sf9: Baculovirus Expression SystemSession: Vector and Cell Engineering, Production, or ManufacturingDate/time: May 12, 2020, 5:30-6:30 p.m. ET Title: Successful Technology Transfer and Clinical Manufacturing for AAV Gene Therapy Vectors: Lessons from Multiple CampaignsSession: AAV Vectors - Clinical StudiesDate/time: May 13, 2020, 5:30-6:30 p.m. ET Title: A Novel AAV Capsid with a Potential of Crossing NHP Blood Brain BarrierSession: AAV Vectors - Virology and VectorologyDate/time: May 13, 2020, 5:30-6:30 p.m. ET Title: Transduction of Various Fragment Forms of Vectorized Anti-Tau Antibodies Using IV Dosing of a Blood Brain Barrier Penetrant A...